Application of CAR-T cell therapy in the treatment of liver cancer
DOI:
https://doi.org/10.54097/q34zj826Keywords:
Liver cancer, CAR-T, immunotherapy, targeted therapy.Abstract
Liver cancer is a frequent malignant tumor with a high fatality rate. However, due to the challenges of early detection and the potentially significant dangers and side effects connected with conventional cancer therapy approaches. Immunotherapy has been a well-liked cancer treatment in recent years due to its efficacy and safety. One of these is chimeric antigen receptor T cells (CAR-T), genetically modified T lymphocytes that recognize and activate T lymphocytes in response to antigens specific to tumors. They aid in the elimination of tumors. Its therapeutic efficacy in the treatment of solid malignancies is currently the subject of extensive research. Despite reaching its fifth generation, CAR-T cell therapy still faces a number of challenges when treating solid malignancies like liver cancer. As a result, this article begins with describing the creation and workings of CAR-T cells. The function it plays in treating liver cancer, including pursuing several ethical goals, was then highlighted. Future treatments for liver cancer and potentially other solid tumors can use this as a benchmark.
Downloads
References
Min JT, et al. Advances and challenges in the treatment of solid tumors with chimeric antigen receptor T cells. Modern Oncology, 2020, 28(18): 3271-3275.
Y. Chen et al. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.Hepatobiliary & Pancreatic Diseases International, 2018, 17: 301-309.
Rafiq S., et al. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nature Review Clinical Oncology, 2020, 17: 147-167.
Zhang C., et al. Engineering CAR-T cells. Biomarker Research, 2017, 5: 22.
Montalbano M, et al. Role of Glypican-3 in the growth, migration and invasion of primary hepatocytes isolated from patients with hepatocellular carcinoma. Cell Oncol, 2018, 41: 169-84.
Galle PR, et al. Biology and significance of alpha - fetoprotein in hepatocellular carcinoma. Liver Int, 2019, 39(12): 2214-2229.
Chen L, et al. CAR-T cell therapy for lung cancer: Potential and perspective. Thorac Cancer, 2022, 13(7): 889-899.
Sun B, et al. Eradication of hepatocellular carcinoma by NKG2D-based CAR-T cells. Cancer Immunol Res., 2019, 7: 1813-1823.
Hossain, N. et al. Phase I experience with a bi-specific CAR targeting CD19 and CD22 in adults with B-cell malignancies. Blood, 2018, 132: 490.
Choe JH, et al. SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Science Translational Med, 2021, 13.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Highlights in Science, Engineering and Technology

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.







